CagriSema vs Petrelintide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Semaglutide + Cagrilintide
CagriSema is a once-weekly injectable that pairs two drugs in one shot: semaglutide (a GLP-1 receptor agonist, the molecule behind Ozempic and Wegovy) and cagrilintide (a long-acting amylin analog). It is being developed by Novo Nordisk for obesity and type 2 diabetes, and in 2025 it cleared its phase 3 REDEFINE trials. It is not yet approved by the FDA, though regulatory filings are underway.
Also: ZP8396
Petrelintide is a long-acting amylin analog from Zealand Pharma, co-developed with Roche, designed as a once-weekly injection for obesity. The pitch is gentler weight loss than GLP-1 drugs but with far less nausea and vomiting. Two phase 2 trials read out positively in 2026 (up to 10.7% weight loss at 42 weeks), and a roughly 7,000-person phase 3 program has started. It is not approved anywhere.
Key Comparison Insights
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
Detailed Comparison
| Attribute | CagriSema | Petrelintide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | The combination works on two different appetite systems at once. Semaglutide mimics GLP-1, a gut hormone that boosts insulin after meals, slows stomach emptying, and signals fullness to the brain. Cagrilintide is a synthetic version of amylin, a hormone co-secreted with insulin from the pancreas, which reduces food intake and reinforces satiety through separate brain circuits in the hindbrain and hypothalamus. The idea, still being characterized, is that hitting GLP-1 and amylin pathways together produces more appetite suppression than either alone. Both components are engineered for slow release so a single weekly dose maintains steady drug levels. | Amylin is a hormone your pancreas releases alongside insulin after meals. It acts on the brainstem to make you feel full sooner, slows stomach emptying, and curbs glucagon after eating. Zealand says amylin signaling also helps restore sensitivity to leptin, the body's long-term fullness signal. Native amylin is unusable as a drug because it clumps into fibrils and lasts minutes, so petrelintide was engineered to stay stable at neutral pH, avoid fibril formation, and last a week. That stability also means it can be co-formulated with other peptides, which is why Roche plans to combine it with its own GLP-1/GIP drug. The theory is that amylin gives more of a natural fullness feeling than GLP-1 drugs do, with fewer GI side effects; the tolerability part looks real so far, the bigger-picture claims still need phase 3. |
| Common Dosing | Limited community data available See research protocols | Not publicly disclosed (once-weekly trial doses) Once weekly |
| Administration | Subcutaneous injection weekly | Subcutaneous injection once weekly |
| Typical Duration | Long-term use expected | 16 weeks (phase 1b) to 42 weeks (phase 2) in completed trials |
| Best Time to Take | Same day each week, any time of day | Same day each week |
Possible Side Effects May vary by individual |
|
|
| Research Summary | This is one of the better-tested experimental obesity drugs because it went straight into large human phase 3 trials rather than living only in animal data. In REDEFINE 1, about 3,400 adults with overweight or obesity but without diabetes were randomized over 68 weeks; CagriSema produced roughly 20.4% average body weight loss versus 14.9% for semaglutide alone, 11.5% for cagrilintide alone, and 3.0% for placebo, with results published in the New England Journal of Medicine in 2025. REDEFINE 2 tested it in adults with type 2 diabetes and also met its endpoints, showing meaningful weight loss and HbA1c improvement compared with placebo. Notably, the headline 20% figure landed below Novo Nordisk's own 25% target, which disappointed investors even though the drug clearly worked. The most common side effects were gastrointestinal: nausea, vomiting, diarrhea, and constipation, consistent with the GLP-1 plus amylin class. CagriSema is not FDA-approved as of mid-2026, so anything sold under that name outside a clinical setting is unregulated. | A 16-week phase 1b trial (48 people) reported up to 8.6% mean weight loss at the highest dose versus 1.7% on placebo, with no early plateau. The phase 2 ZUPREME-1 trial (493 people with obesity or overweight, mean BMI 37) reported in March 2026 up to 10.7% mean weight loss at 42 weeks versus 1.7% on placebo. That is clearly less than semaglutide or tirzepatide produce, but tolerability stood out: no vomiting at the maximally effective dose, and side-effect dropouts (4.8%) no higher than placebo (4.9%). ZUPREME-2 (220 people with obesity and type 2 diabetes) reported in October 2026: 7.4-9.2% weight loss at 28 weeks versus 2.0% on placebo, placebo-adjusted HbA1c drops of 0.61-0.88 points, and GI dropouts of 1.9% versus 1.7%. Roche and Zealand have started phase 3a (ZUPREME-3, -4 and -5, about 7,000 people in total, including a cardiovascular-disease population). Honest take: a well-tolerated, moderate-strength drug whose real value may be as a combination partner, and the full peer-reviewed phase 2 data are still pending. |
Frequently Asked Questions: CagriSema vs Petrelintide
What is the difference between CagriSema and Petrelintide?
CagriSema is a weight loss peptide that cagrisema is a once-weekly injectable that pairs two drugs in one shot: semaglutide (a glp-1 receptor agonist, the molecule behind ozempic and wegovy) and cagrilintide (a long-acting amylin analog). it is being developed by novo nordisk for obesity and type 2 diabetes, and in 2025 it cleared its phase 3 redefine trials. it is not yet approved by the fda, though regulatory filings are underway. Petrelintide is a weight loss peptide that petrelintide is a long-acting amylin analog from zealand pharma, co-developed with roche, designed as a once-weekly injection for obesity. the pitch is gentler weight loss than glp-1 drugs but with far less nausea and vomiting. two phase 2 trials read out positively in 2026 (up to 10.7% weight loss at 42 weeks), and a roughly 7,000-person phase 3 program has started. it is not approved anywhere. The main differences lie in their mechanisms of action and clinical applications.
Which is better, CagriSema or Petrelintide?
Neither is universally "better" - the choice depends on your specific goals. CagriSema is typically used for weight loss purposes, while Petrelintide is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can CagriSema and Petrelintide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using CagriSema and Petrelintide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.